Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the D... (an inhaled long-actingbronchodilator sal...)

HOME >> BIOLOGY >> TECHNOLOGY

Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS

Date:5/20/2008

an inhaled long-acting bronchodilator, salmeterol, to help prevent and reduce airway constriction. Advair is for people who still have symptoms on another asthma controller, or whose disease severity clearly warrants treatment with two maintenance therapies.

About Observational Studies

This was an observational study. Unlike randomized controlled trials, observational studies such as these do not imply causality, though they can imply association of the treatment to the outcome. Even though outcomes were adjusted for severity using known subject demographics, asthma-related outcomes are influenced by many factors, such as prescriber and clinical factors. These factors were not measured or evaluated in this study.

Important Information about Advair

Advair won't replace fast-acting inhalers for sudden symptoms and should not be taken more than twice a day. Advair contains salmeterol. In patients with asthma, medicines like salmeterol may increase the chance of asthma-related death. So Advair is not for people whose asthma is well controlled on another controller medicine. People should speak to their doctor about the risks and benefits of treating their asthma with Advair. People taking Advair should see their doctor if their asthma does not improve. Thrush in the mouth and throat may occur. People should tell their doctor if they have a heart condition or high blood pressure. Some people may experience increased blood pressure, heart rate, or changes in heart rhythm. Advair Diskus is for patients 4 years and older. For patients 4 to 11 years old, Advair Diskus 100/50 is for those who have asthma symptoms while on an inhaled corticosteroid. Advair HFA is for patients 12 years and older.

For more information about Advair please visit http://www.gsk.com.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
2. Allergy Standards LTD to Attend 2008 American Academy of Allergy, Asthma and Immunology Conference
3. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
4. Drug Reduces Airway Mucus in Preclinical Asthma Model
5. AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
6. One Year On, ALLERCA Hypoallergenic Cats Bring Sneeze Free Companionship to Allergy and Asthma Sufferers
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
9. Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management
10. Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
11. Top Cancer Hospitals in Denmark and Netherlands First in Europe to Treat Patients With RapidArc(TM) Radiotherapy

Post Your Comments:

Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the D...(an inhaled long-actingbronchodilator sal...)